Fatal

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Friday, April 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

WHY AUTO INSURANCE COSTS ARE RISING AND WHAT CONSUMERS CAN DO ABOUT IT

Retrieved on: 
Wednesday, April 10, 2024
St. Paul's Episcopal Church, Workforce, ISS, Glass, Insurance, Risk, Policy, Government, Harvard Kennedy School, Distracted driving, Partnership, Senate, Lipscomb University, Public policy, Abilene Christian University, COVID-19, Fatality, Commerce, Crash, Episcopal Church, Fatal, Harvard University

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9219951-american-property-casual...

Key Points: 
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9219951-american-property-casual...
    The answer is for the simple reason that the cost of the things auto insurance pays for has been rising faster than premiums.
  • Some of the key contributors to rising costs include cumulative years of record-high inflation that have greatly increased the cost of repairing and replacing cars.
  • All indicators suggest elevated auto repair and replacement costs will stretch well into 2024 and potentially beyond.
  • 5 Consumer Tips to Lower Your Auto Insurance Premiums:
    Contact your insurance company or agent for a policy review.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

New AHF Campaign Warns Syphilis Can be Fatal to Your Baby

Retrieved on: 
Monday, January 8, 2024
Other Health, Practice Management, Advertising, Social Activism, Communications, General Health, Women, Philanthropy, Infectious Diseases, Men, Baby, Maternity, Foundation, Family, AIDS, Consumer, Health, Congenital syphilis, URL, Multimedia, Infection, AHF, STI, Fatal, Mother, AIDS Healthcare Foundation, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) has updated and relaunched a groundbreaking billboard and awareness campaign, “Syphilis Can be Fatal to Your Baby,” warning of the dangers of congenital syphilis which can be fatal to babies if the infection goes undiagnosed and untreated in mothers.

Key Points: 
  • AIDS Healthcare Foundation (AHF) has updated and relaunched a groundbreaking billboard and awareness campaign, “Syphilis Can be Fatal to Your Baby,” warning of the dangers of congenital syphilis which can be fatal to babies if the infection goes undiagnosed and untreated in mothers.
  • View the full release here: https://www.businesswire.com/news/home/20240108069539/en/
    The campaign artwork features an illustration of a visibly pregnant person with the headline, “Syphilis Can be Fatal to Your Baby,” driving to the website URL “FreeSTDCheck.org.” AHF’s congenital syphilis campaign consists of billboards, posters, transit shelters, 2-sheets, buses, bus benches, and street kiosks and began posting nationwide last week.
  • The campaign will run for three months in most markets and is appearing in California, Florida, Georgia, Illinois, Louisiana, Maryland, Mississippi, and Nevada.
  • AHF offers free sexually transmitted infection (STI) testing and treatment at 36 Wellness Centers in 14 states and Washington, DC.

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, FDA, Health, Pharmaceutical, MSD, Medicine, DSM-IV codes, PD-L1, NYSE, Potassium, Food, Progression-free survival, RECIST, Merck & Co., Head, Pneumonia, Blood transfusion, Dana–Farber Cancer Institute, Risk, Lymphocyte, Hypoxia, Everolimus, Bleeding, IMDC, Fatigue, Sepsis, Patient, Pregnancy, PFS, Effectiveness, Belzutifan, Week, VHL, VEGF, RCC, COVID-19, PD-1, Creatinine, TKI, ORR, Harvard Medical School, Death, Anemia, Fatal, Sodium, Hospital, Pleural effusion, HIV disease progression rates, MRK, Pharmaceutical industry, Birth control, Merck

Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.

Key Points: 
  • Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
  • Patients could have received up to three prior treatment regimens and were required to have measurable disease per RECIST v1.1.
  • Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients.
  • Adverse reactions that required dose reduction in ≥1% of patients were hypoxia (5%) and anemia (3.2%).

FHWA and Roadway Safety Foundation Honor 10 Life-Saving Projects

Retrieved on: 
Thursday, November 30, 2023
VDOT, State, Toll road, Fatality, Crash, Virginia Department of Transportation, Pedestrian, Fatal, Delaware Department of Transportation, Travel, Safety, Interstate 35, Development, PANYNJ, RSF, NDOT, Friction, Federal Highway Administration, Florida Department of Transportation, American Highway Users Alliance, FHWA, Nevada Department of Transportation, Road traffic safety, Creativity, APC, Authority, Interstate Highway System, Bicycle, Death, FDOT, Minnesota Department of Transportation, Injury, Environment, Road, Road transport, Video game, Texas Department of Transportation, California Department of Transportation, NCDOT, Transport

WASHINGTON, Nov. 29, 2023 /PRNewswire/ -- Ten innovative highway safety projects, representing the very best of the nation's roadway safety practices, were honored today with National Roadway Safety Awards at a Capitol Hill ceremony. Two additional projects received honorable mentions.

Key Points: 
  • The awards were presented by the leadership of the Federal Highway Administration (FHWA) and the Roadway Safety Foundation (RSF), which jointly sponsor the competition.
  • Begun in 1999, the biennial National Roadway Safety Awards honor initiatives that improve roadway safety at the state and local level.
  • "The stubbornly elevated fatality numbers underscore the urgent need for innovations like the National Roadway Safety Award honorees' projects," said Roadway Safety Foundation Executive Director Bruce Hamilton.
  • Applicants for the National Roadway Safety Awards were encouraged to nominate projects and programs that are innovative, effective and cost efficient.

DELAWARE DEPARTMENT OF TRANSPORTATION HONORED FOR REDUCING SEVERE CRASHES AT INTERSECTIONS USING ALL-WAY STOP CONTROL

Retrieved on: 
Wednesday, November 29, 2023
Safety, Travel, Delaware Department of Transportation, Federal Highway Administration, California Department of Transportation, Fatality, Death, American Highway Users Alliance, Crash, Honorable Mention, NHTSA, Pedestrian, Traffic engineering, Fatal, NDOT, Injury, Environment, Road, Video game, Transport

WASHINGTON, Nov. 29, 2023 /PRNewswire/ -- The Delaware Department of Transportation (DelDOT) was honored today with a 2023 National Roadway Safety Award for significantly reducing fatal and serious injury crashes at 20 intersections by converting them to all-way stops.

Key Points: 
  • Between 2017 and 2020, DelDOT converted 20 low-volume intersections statewide, mostly in rural and suburban areas, from two-way to all-way stops.
  • In the two years after the change (2021 and 2022), the number of crashes at those intersections fell by 71 percent overall.
  • Fatal crashes dropped by 75 percent, while crashes with injuries plummeted by 90 percent.
  • Now, DelDOT engineers can consider the usage of all-way stops similar to traditional preliminary steps, such as installing larger stop signs.

Impaired Driving Spikes During Holiday Period

Retrieved on: 
Tuesday, November 28, 2023
Holiday, Distracted driving, Fatigue, Self-assessment, Incidence, Coffee, Radio, Insurance, New Year's Eve, Crash, Fatality, Caffeine, Male, NHTSA, Death, New Year's, Plasma protein binding, Drinking, Fatal, Female, DUI, Aggression, FCCLA, Injury, Travel, Education, Almost Home, Ridesharing, Road transport

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- The year-end holiday period from Thanksgiving through New Year's is always one of the most dangerous times on U.S. roads and highways, with a spike in crashes that often result in serious injuries or death. The National Road Safety Foundation, a non-profit group that for more than 60 years has been promoting safe driving through education, says the increased risk comes from a combination of factors that include impairment from alcohol and drugs coupled with a higher incidence of drowsy driving.

Key Points: 
  • "Passengers can also play a role in keeping everyone safe by speaking up if a driver is impaired, drowsy or driving recklessly.
  • Christmas and New Year's Eve were especially dangerous, with more drunk-driving fatalities than during any other holiday period.
  • The National Road Safety Foundation has free resources on impaired and drowsy driving, including "Almost Home," a compelling 18-minute video and a drowsiness self-assessment quiz.
  • They can be downloaded at www.nrsf.org/resources
    The National Road Safety Foundation, Inc., a 501 (c)(3) non-profit organization, produces free videos and teaching materials on distracted driving, speed and aggression, impaired driving, drowsy driving, driver proficiency, pedestrian safety and a host of other safety issues.

Endo Launches Colchicine Capsules, Generic Version of MITIGARE®

Retrieved on: 
Thursday, November 2, 2023
Aplastic anemia, Patient, Abdominal pain, Clarithromycin, Food, Fatal, Thrombocytopenia, Vomiting, Diarrhea, OTC, Colchicine, Endo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nausea, Bone marrow suppression, Endo International, Senior, Ciclosporin, Rhabdomyolysis, Risk, Capsule, Leukopenia, Pancytopenia, Safety, Pain, Granulocyte, Death, Pharmaceutical industry, Dairy, Dietary supplement, CYP3A4

DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.

Key Points: 
  • DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.
  • This is the first generic colchicine capsule approved by the U.S. Food and Drug Administration.
  • Patients with renal or hepatic impairment should not be given colchicine with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors.
  • Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity.

Endo Launches Colchicine Capsules, Generic Version of MITIGARE®

Retrieved on: 
Thursday, November 2, 2023
Aplastic anemia, Patient, Abdominal pain, Clarithromycin, Food, Fatal, Thrombocytopenia, Vomiting, Diarrhea, OTC, Colchicine, Endo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nausea, Bone marrow suppression, Endo International, Senior, Ciclosporin, Rhabdomyolysis, Risk, Capsule, Leukopenia, Pancytopenia, Safety, Pain, Granulocyte, Death, Pharmaceutical industry, Dairy, Dietary supplement, CYP3A4

DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.

Key Points: 
  • DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.
  • This is the first generic colchicine capsule approved by the U.S. Food and Drug Administration.
  • Patients with renal or hepatic impairment should not be given colchicine with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors.
  • Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity.